MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 23.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,604 shares of the company’s stock after purchasing an additional 20,551 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.05% of Taysha Gene Therapies worth $188,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Hsbc Holdings PLC increased its holdings in shares of Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock valued at $36,000 after purchasing an additional 8,076 shares in the last quarter. Virtus ETF Advisers LLC increased its holdings in shares of Taysha Gene Therapies by 43.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company’s stock valued at $55,000 after purchasing an additional 9,494 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Taysha Gene Therapies by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock valued at $6,182,000 after purchasing an additional 9,591 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock valued at $820,000 after purchasing an additional 11,390 shares in the last quarter. Finally, Ground Swell Capital LLC purchased a new position in shares of Taysha Gene Therapies during the 4th quarter valued at approximately $25,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock opened at $2.71 on Monday. The company’s fifty day moving average price is $1.92 and its 200 day moving average price is $1.90. Taysha Gene Therapies, Inc. has a 1 year low of $1.05 and a 1 year high of $4.32. The stock has a market capitalization of $581.73 million, a P/E ratio of 4.30 and a beta of 0.90. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.30 million for the quarter, compared to analysts’ expectations of $1.48 million. During the same quarter in the previous year, the company posted ($0.10) EPS. As a group, equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. JMP Securities lifted their target price on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a “market outperform” rating in a report on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Monday, April 28th. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Finally, Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, May 16th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $7.00.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.